Financings Roundup
Zafgen $21M Raise to Move Beloranib Beyond Phase IIa
Privately held Zafgen Inc. secured a hefty Series D equity raise of $21 million, which will move obesity candidate beloranib (ZGN-440) beyond the Phase IIa trial that was initiated last month.